Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial
Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456925003517?dgcid=rss_sd_all
Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456925003517?dgcid=rss_sd_all
“Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial.” European Urology Focus.
@article{article116737,
title = {Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456925003517?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...